Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback